Terence Kohler - OptiNose Chief Officer
| OPTN Stock | USD 0.40 0.03 8.11% |
Executive
Terence Kohler is Chief Officer of OptiNose
| Address | 1020 Stony Hill Road, Yardley, PA, United States, 19067 |
| Phone | 267 364 3500 |
| Web | https://www.optinose.com |
OptiNose Management Efficiency
The company has return on total asset (ROA) of (0.1032) % which means that it has lost $0.1032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.505) %, meaning that it created substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities. At this time, OptiNose's Return On Capital Employed is very stable compared to the past year. As of the 22nd of November 2024, Return On Equity is likely to grow to 0.43, while Return On Tangible Assets are likely to drop (0.35). At this time, OptiNose's Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 4.2 M, though Net Tangible Assets are likely to grow to (61.9 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dong Yu | Dynavax Technologies | N/A | |
| Jeffrey Plumer | Evolus Inc | N/A | |
| MP MBA | Amphastar P | N/A | |
| Peter Norman | Alkermes Plc | N/A | |
| Robert MD | Dynavax Technologies | 70 | |
| Donn Casale | Dynavax Technologies | N/A | |
| Tomoko YamagishiDressler | Evolus Inc | N/A | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Todd Anthony | Cumberland Pharmaceuticals | 63 | |
| David Boyer | Neurocrine Biosciences | 45 | |
| Michael MD | Ironwood Pharmaceuticals | 65 | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Karen Esq | Intracellular Th | 62 | |
| Willie MD | Intracellular Th | N/A | |
| MBA MPH | Amphastar P | N/A | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| YatPui Au | Regencell Bioscience Holdings | 50 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Jon Knight | Kamada | 58 | |
| Chaime Orlev | Kamada | 54 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
Management Performance
| Return On Equity | -10.5 | ||||
| Return On Asset | -0.1 |
OptiNose Leadership Team
Elected by the shareholders, the OptiNose's board of directors comprises two types of representatives: OptiNose inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OptiNose. The board's role is to monitor OptiNose's management team and ensure that shareholders' interests are well served. OptiNose's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OptiNose's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Krick, Vice Officer | ||
| Michele MBA, VP CFO | ||
| Terence Kohler, Chief Officer | ||
| Paul Spence, Chief Officer | ||
| John Messina, Sr Affairs | ||
| Jonathan Neely, Vice President - Investor Relations and Business Operations | ||
| Karen Brophy, Chief Resources | ||
| Michael Esq, Chief Secretary | ||
| Victor Clavelli, Chief Officer | ||
| Per MD, CoFounder AS | ||
| Peter Miller, CEO, Director | ||
| MPH MD, CEO Director |
OptiNose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OptiNose a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.5 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 99.85 M | ||||
| Shares Outstanding | 150.83 M | ||||
| Shares Owned By Insiders | 5.98 % | ||||
| Shares Owned By Institutions | 76.80 % | ||||
| Number Of Shares Shorted | 8.57 M | ||||
| Price To Earning | (3.41) X |
Pair Trading with OptiNose
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OptiNose position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OptiNose will appreciate offsetting losses from the drop in the long position's value.Moving together with OptiNose Stock
| 0.61 | ME | 23Andme Holding | PairCorr |
| 0.89 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.65 | VCNX | Vaccinex | PairCorr |
Moving against OptiNose Stock
| 0.8 | BMY | Bristol Myers Squibb | PairCorr |
| 0.67 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.65 | GILD | Gilead Sciences | PairCorr |
| 0.53 | VRDN | Viridian Therapeutics | PairCorr |
| 0.51 | KZR | Kezar Life Sciences | PairCorr |
The ability to find closely correlated positions to OptiNose could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OptiNose when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OptiNose - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OptiNose to buy it.
The correlation of OptiNose is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OptiNose moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OptiNose moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OptiNose can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 0.553 | Quarterly Revenue Growth 0.031 | Return On Assets (0.10) | Return On Equity (10.51) |
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.